ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该方案评价了6个月口服阿昔洛韦抑制性治疗新生儿单纯疱疹病毒病仅限于皮肤，眼睛和口腔。这是一项双盲、随机研究。静脉注射阿昔洛韦14天后，新生儿将随机接受抑制性阿昔洛韦或接受相同口味的安慰剂，为期6个月。任何一组中的皮肤HSV复发将用开放标签口服阿昔洛韦治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol evaluates the use of 6 months suppressive oral acyclovir therapy in neonates following herpes simple virus disease limited to the skin, eye, and mouth. This is a double-blind, randomized study. Following 14 days of IV acyclovir, neonates will be randomized to receive suppressive acyclovir or to receive identically flavored placebo for a period of six months. Cutaneous HSV recurrences in either group will be treated with open label oral acyclovir.